Aptamer Sciences Inc. has filed an IND application with the Korean Ministry of Food and Drug Safety seeking clearance to conduct a phase I trial of AST-201 in patients with GPC3-positive advanced solid tumors.
Biomunex Pharmaceuticals SAS has signed an exclusive license and exploitation agreement with Institut Curie for the development of a new class of antibodies.
Vidac Pharma Holdings plc has released promising results for VDA-1275 in mouse cancer and human cellular organoid models of solid tumors, with VDA-1275 showing efficacy as a monotherapy and synergistic effects in combination with sorafenib and cisplatin.
A new study published by researchers from the Tokyo University of Science (TUS) unveiled a new machine learning-aided, non-invasive imaging framework for rapid liver lipid visualization, which could help diagnose and treat steatotic liver diseases (SLD).
CSPC Pharmaceutical Group Ltd. has announced FDA approval of an IND application for JMT-106, a bispecific fusion protein drug, for glypican-3 (GPC3)-positive solid tumors.
Researchers at Daegu-Gyeongbuk Medical Innovation Foundation and Korean Research Institute of Bioscience and Biotechnology have identified acetyl-CoA carboxylase (ACC) inhibitors reported to be useful for the treatment of liver cancer.
Pasithea Therapeutics Corp. has reported promising preclinical results from two in vivo studies evaluating the antitumor efficacy of PAS-004 (CIP-137401), a small-molecule allosteric inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK 1/2), in NRAS mutation cancer xenograft models.